Surgical Advances in the Management of Gastrointestinal Cancers

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 15 January 2026 | Viewed by 722

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgery, Dalhousie University, Halifax, NS B3H 4R2, Canada
Interests: hepatobiliary surgery; transplant oncology; pancreatic cancer; ischemia reperfusion; minimally invasive surgery; precision medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of surgical oncology has entered a transformative phase regarding the management of gastrointestinal (GI) cancers, fueled by innovations in technology, multidisciplinary collaboration, and an evolving understanding of tumor biology. Surgical advances in gastrointestinal (GI) oncology now aim to improve survival and quality of life by optimizing the extent of resection, integrating novel perioperative therapies, and personalizing treatment strategies based on tumor-specific characteristics. While the foundational principles of surgery remain, we are now equipped with more sophisticated tools to challenge traditional limitations and rethink how we approach complex malignancies.

This evolution has been particularly evident in esophageal, gastric, pancreatic, and colorectal cancers, where minimally invasive approaches, enhanced imaging, and extended resectability criteria have significantly expanded the surgical armamentarium. Advances such as robotics-assisted resections, fluorescence-guided surgery, and real-time intraoperative pathology are helping refine margins, minimize morbidity, and expedite recovery. Simultaneously, incorporating molecular profiling, circulating tumor DNA, and response-adaptive strategies helps define surgical indications with greater precision.

As we push the boundaries of operability, we must also recognize the challenges. Patient selection remains critical, particularly in the context of advanced or borderline resectable disease and requires robust multidisciplinary decision-making. Enhanced recovery protocols and improved perioperative care have allowed us to offer surgery to increasingly complex patients. However, optimal outcomes depend on integration with systemic and radiation therapies. Moreover, as immunotherapies and biologics become more central in GI oncology, their interplay with surgery demands closer study, especially in terms of timing, sequencing, and immunologic implications.

Given the dynamic progress in this field, there is a pressing need to consolidate emerging knowledge on surgical innovation, patient stratification, and outcome optimization. We are pleased to invite you to contribute to this Special Issue, “Surgical Advances in the Management of Gastrointestinal Cancers”, hosted by Current Oncology. Original research articles and reviews are welcome. We encourage submissions that explore novel surgical techniques, multimodal strategies, biomarker-driven decisions, and institutional or regional data reflecting evolving standards of care. Contributions that analyze surgical education, resource allocation, and policy development in the context of advancing GI cancer care are also of particular interest. Through this Special Issue, we aim to foster a deeper understanding of how surgical innovation can reshape the future of gastrointestinal oncology.

Research areas may include (but are not limited to) the following:

  1. Precision medicine concepts in surgical oncology;
  2. Technological surgical advancements to improve cancer care;
  3. Improving patient-reported outcomes after surgery.

I look forward to receiving your contributions.

Dr. Boris Luis Gala-López
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancers
  • surgical innovation
  • multimodal therapy
  • precision oncology
  • minimally invasive surgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 465 KB  
Article
Primary Anastomosis Versus Hartmann’s Procedure in Obstructing Colorectal Cancer: A Retrospective Cohort Study
by Abbas Aras
Curr. Oncol. 2025, 32(11), 636; https://doi.org/10.3390/curroncol32110636 - 13 Nov 2025
Viewed by 402
Abstract
Introduction: The objective of this study was to analyze and compare the outcomes of two surgical techniques in the emergency management of obstructed colorectal carcinoma. Methods: This is a retrospective analysis of patients’ data from a tertiary referral university hospital. The medical [...] Read more.
Introduction: The objective of this study was to analyze and compare the outcomes of two surgical techniques in the emergency management of obstructed colorectal carcinoma. Methods: This is a retrospective analysis of patients’ data from a tertiary referral university hospital. The medical records of patients who underwent emergency surgery for obstructed colorectal cancer between May 2014 and August 2019 were evaluated. The cases were divided primarily into two groups: Primary Resection and Anastomosis (PRA) and Hartmann’s Procedure (HP). The clinical characteristics, peri-operative outcomes and oncological results including early postoperative complications, morbidity and mortality (30-day, 1-year and 5-year survival) were compared between groups. Results: In this retrospective study, 110 patients with obstructing colorectal cancer undergoing emergency surgery were analyzed. Patients were divided into two groups: 65 cases of Primary Resection and Anastomosis (PRA) and 45 cases of Hartmann’s Procedure (HP). PRA patients had significantly shorter hospital stays (8.7 ± 4.1 vs. 11.2 ± 5.2 days, p = 0.02), lower complication rates (33% vs. 66%, p = 0.003), and superior survival outcomes, with a 5-year survival rate of 33.8% compared to 22.2% in the HP group (p = 0.003). Subgroup analysis revealed significant differences, including higher complication rates and repeat surgery requirements in patients with a diverting ostomy or undergoing resection without anastomosis. Conclusion: PRA demonstrated favorable perioperative and long-term outcomes compared to HP in the emergency management of obstructing colorectal cancer. These findings highlight the potential benefits of avoiding permanent stoma formation when appropriate patient selection criteria are met. Full article
(This article belongs to the Special Issue Surgical Advances in the Management of Gastrointestinal Cancers)
Show Figures

Figure 1

Back to TopTop